1. Introduction {#s0005}
===============

Interaction between drugs represents a major clinical concern for health care professionals and their patients. It occurs when one therapeutic agent either alters the concentrations or the biological effect of another agent ([@b0040]). Many clinically important drug interactions are the result of induction or inhibition of cytochrome P450 (CYP) enzymes, the major drug-metabolizing enzymes mainly present in the liver ([@b0120; @b0095]). It has been estimated that 70% of human drug oxidation can be attributed to six main enzymes CYP1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 ([@b0115]). Patients affected by both diabetes type 2 DM and epilepsy can be treated by pioglitazone and carbamazepine at the same time. Pioglitazone (PG) is a thiazolidinedione compound used in the treatment of type 2 DM. It is an insulin sensitizer that acts as an agonist of the peroxisome proliferator-activated receptor subtype gamma (PPAR-γ), ([@b0125; @b0070]). It is well-absorbed, with a mean absolute bioavailability of 83% and reaching maximum concentrations in around 1.5 h ([@b0055; @b0030]). Moreover, it is extensively metabolized by hydroxylation and oxidation to active and inactive metabolites in the liver predominantly via cytochrome P450 (CYP) isoenzymes, CYP2C8 and CYP3A4 ([@b0055; @b0030]).

Carbamazepine (CBZ) is one of the most commonly prescribed antiepileptic drugs and is also used in the treatment of trigeminal neuralgia and psychiatric disorders, particularly bipolar depression ([@b0035]). It has a dissolution dependent oral bioavailability due to its low solubility in water (113 μg ml^−1^, 25 °C) exhibiting a slow and irregular gastrointestinal absorption ([@b0100; @b0010]). CBZ is a potent inducer of CYP isoenzymes CYP1A2, CYP2C9, CYP2C19, and CYP3A4 ([@b0005; @b0105]). However, it is metabolized by CYP3A4 to give carbamazepine-10,11-epoxide, the major active metabolite representing 80% of CBZ in man ([@b0060; @b0080]). So, CBZ shows a relatively short half-life, in chronic treatment, due to autoinduction of the drug metabolism ([@b0045]). Furthermore, its half-life may be shortened by coadministration of other CYP3A4 inducer drugs ([@b0035]).

PG showed in vitro inductive effects on CYP3A4 ([@b0095]). This could influence pharmacokinetic of CBZ. Alteration in pharmacokinetics of such antiepileptic may cause toxicity or loss of seizure control. Therefore, this study was conducted to assess the possibility of potential interaction of PG with CBZ.

2. Materials and Methods {#s0010}
========================

2.1. Animals {#s0015}
------------

Six healthy male rabbits with mean weight 3.4 ± 0.12 kg, aged 7--9 months were enrolled in the study. The rabbits were obtained from Asdda for animal production and welfare center, where follow up care and clinical examination were performed and rabbits' health state was certified (khanunis, Palestine). Rabbits were fasted for 12 h with free access to water by ad libitum before the beginning of the study.

The study was carried out at the Al-Azhar University-Gaza, College of Pharmacy, Gaza, Palestine. The study was approved by the institutional ethics committee and was conducted under supervision of a veterinary physician.

2.2. Study design {#s0020}
-----------------

A single dose, two-crossover design study was conducted in rabbits. There was a washout period of one week between the two doses. The rabbits were divided into two groups. The first one received a 70 mg dose of CBZ oral suspension, whereas the second group received the same dose of CBZ co-administered with a single dose 1.5 mg of PG as a suspension prepared in laboratory. PG tablets were pulverized and a weight of the powder equivalent to 15 mg PG was suspended in 20 ml distilled water. Carbamazepine suspension (2%, Tegretol, Novartis) and pioglitazone tablet (30 mg, Actos, Takeda) were purchased from a local pharmacy (Gaza, Palestine). After one week the second group received CBZ alone and the first received CBZ concurrently with PG to complete the cross-over design. The dose was given by means of a syringe connected to an oral gavage. It was put in the corner of the mouth and the liquid was pushed down slowly, to avoid choking. General clinical safety was assessed by physical examination during the study, washout period and at the end of the study.

2.3. Blood sampling {#s0025}
-------------------

Rabbits were placed in the rabbit restraining box device. The marginal ear vein was located and the hair was removed. Gentle stroking and tapping of the ear may make the vein more visible. Local anesthetic was applied to prevent the jerking of the rabbit as a result of venipuncture 15 min before starting the study by inserting a small needle (23 gauge) butterfly attached to a syringe in the marginal ear vein ([@b0075]). Serial venous blood samples were collected (1 ml) in vacutainer tubes according to the time schedule 0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 24.0 and 48 h after receiving the dose. Blood samples were centrifuged at 3,000 rpm for 5 min and serum was transferred into clean plastic tubes. Serum samples (ca. 200 μl) were kept in refrigerator until being analyzed within 24 h.

2.4. Analysis of serum samples {#s0030}
------------------------------

The analysis was performed by the carbamazepine kit based on chemiluminescent enzyme immunoassay (CLEIA) and Immulite 1000 immunoassay system (Siemens Healthcare Diagnostics).

2.5. Pharmacokinetic analysis {#s0035}
-----------------------------

The plasma pharmacokinetic parameters were estimated, which included the observed maximum plasma concentration C~max~, the time to reach C~max~, (T~max~) and the area under the plasma concentration--time curve from 0 h to last measurable concentration (AUC~0-t~) and 0 h to infinity (AUC~0-∞~). C~max~ and T~max~ were directly determined from the serum concentration versus time curves. The area under the curve from 0 h to t (AUC~0-t~) was calculated by the linear trapezoidal rule. The area under the curve from 0 h to infinity (AUC~0-∞~) was estimated by summing the area from AUC~0-t~ and AUC~0-∞~, where AUC~0-∞~ = AUC~0-t~ + C~t~ / k~e~, with 'C~t~' defined as the last measured serum concentration at time t, and k~e~ is the elimination rate constant. The elimination rate constant k~e~ was estimated by the least squares regression of plasma concentration--time data points lying in the terminal region by using semilogarithmic dependence that corresponds to first-order kinetics. The half-life t~1/2~ was calculated as 0.693/k~e~. Pharmacokinetic analysis was performed by means of model independent method (Non-Compartmental Approach) WinNonlin Professional Software (Version 6.3, Pharsight Corporation, Cary, NC).

2.6. Statistical analysis {#s0040}
-------------------------

Analysis of Variance (ANOVA) was used to compare the calculated pharmacokinetic parameters of carbamazepine for the two periods, using general linear model procedures, in which sources of variation were subject and period. The statistical analysis was performed using SPSS, version 16. P-value ⩽ 0.05 was considered statistically significant.

3. Results {#s0045}
==========

The mean plasma concentrations of carbamazepine when administered alone or in combination with pioglitazone are shown in [Fig. 1](#f0005){ref-type="fig"}. The concentration time profile obviously indicated that the two periods are comparable. The mean pharmacokinetic parameters of carbamazepine administered alone or in combination with pioglitazone as well as the statistical significance following their comparison are given in [Table 1](#t0005){ref-type="table"}.

In the two periods of treatments, C~max~, T~max~, AUC~0-t~, AUC~0-∞~, t ~½~ and k~e~ for CBZ were administered alone and co-administered with PG. The mean peak plasma concentration C~max~ was 4.33 ± 2.4 μg/mL versus 4.76 ± 2.1 μg/mL, t~max~, time taken to reach C~max~, was 2.91 ± 1.11 h versus 3.6 ± 1.83 h, total area under the curve AUC~0-t~ was 64.90 ± 43.6 μg·h/mL versus 102.90 ± 66.9 μg·h/mL, AUC~0-∞~ was 74.0 ± 52.6 μg·h/mL versus 124.3 ± 85 μg·h/mL, t ~½~ was 14.10 ± 2.5 h versus 16.43 ± 6.43 h and elimination rate constant was 0.050 ± 0.009 h^−1^ versus 0.057 ± 0.049 h^−1^, respectively.

Statistically insignificant differences were found in all pharmacokinetic parameters of CBZ in both cases (P \> 0.05).

4. Discussion {#s0050}
=============

The six healthy male rabbits completed the study without any deviations. The utility of rabbit as a model to study drug--drug interactions is well documented ([@b0110; @b0090]). All six rabbits had completed the study and there were no death or replacement during the study. Clinical physical examination during and post study indicated no abnormalities. The present study showed good tolerability of both formulations.

As recognized, the primary organ involved in drug metabolism is the liver which includes a very important family of enzymes called cytochrome P450 (CYP). More than 50% of all drugs are metabolized at least in part by CYP3A4 or CYP2D6 ([@b0050]). As a result, many drug interactions are a consequence of inhibition or induction of cytochrome P450 (CYP) enzymes ([@b0040]). As known, carbamazepine is metabolized by CYP3A4 to give carbamazepine-10,11-epoxide ([@b0060]), so co administration of CBZ with CYP3A4 inducers or inhibitors can affect its plasma concentration ([@b0035]). Previous studies demonstrated that the mean serum concentration of carbamazepine was lower when the drug was given in combination with CYP3A4 inducers such as phenytoin (59·4%), primidone (58·2%), phenobarbital (65·7%) and valproate (83·0%) than when carbamazepine was given alone (100%), ([@b0015; @b0085]). PG has an inductive effect on CYP3A4 activity, which was established by in vitro testing using primary human hepatocytes ([@b0095]). An *in vivo* study showed similar effects of PG, where it was found that sub-chronic concurrent administration of PG (10 mg/kg) with phenytoin (30 mg/kg), antiepileptic drug metabolized mainly by CYP3A4 ([@b0025; @b0065]), was associated with significant reduction in its plasma concentration in rats.

Despite in vitro effect of PG on CYP3A4, the pharmacokinetics of CBZ was not affected in rabbits. In vitro results are not necessarily extrapolated to *in vivo* model. St John's Wort, in vitro CYP3A4 inducer, did not significantly affect the pharmacokinetic parameters of CBZ ([@b0020]).

We think that the suitable interpretation of our results that pioglitazone has the potential to cause drug--drug interactions through induction of CYP3A4 if sufficient concentration (50 μM) is achieved in the liver.

5. Conclusions {#s0055}
==============

It has been found that PG does not affect the pharmacokinetics of CBZ.
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###### 

Summary of mean pharmacokinetic parameters of CBZ 70 mg alone and in combination with 1.5 mg of PG in rabbits (n = 6).

  Pharmacokinetic parameters[a](#tblfn1){ref-type="table-fn"}   CBZ[b](#tblfn2){ref-type="table-fn"} Mean ± SD[d](#tblfn4){ref-type="table-fn"}   CBZ + PG[c](#tblfn3){ref-type="table-fn"} Mean ± SD[d](#tblfn4){ref-type="table-fn"}   p-Value[e](#tblfn5){ref-type="table-fn"}
  ------------------------------------------------------------- --------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ------------------------------------------
  C~max~ (μg/ml)                                                4.33 ± 2.41                                                                       4.76 ± 2.16                                                                            0.697
  T~max~ (h)                                                    2.91 ± 1.11                                                                       3.6 ± 1.83                                                                             0.328
  AUC ~0-48~ (μg.h/ml)                                          64.90 ± 43.6                                                                      102.90 ± 66.9                                                                          0.328
  AUC ~0-∞~ (μg.h/ml)                                           74.00 ± 52.6                                                                      124.30 ± 85                                                                            0.726
  t~½~ (h)                                                      14.10 ± 2.5                                                                       16.43 ± 6.43                                                                           0.269
  K~e~ (h^−1^)                                                  0.050 ± 0.0090                                                                    0.057 ± 0.049                                                                          0.245

Abbreviations are C~max~: Maximum serum concentration, T~max~: Time taken to reach C~max~, AUC~0-48~: Area under the curve from 0 h to 48 h, AUC~0-∞~: Area under the curve from 0 h to infinity, t~1/2~: Terminal half-life and K~e~: Terminal elimination constant.

Rabbits received 70 mg CBZ.

Rabbits received CBZ in combination with 1.5 mg PG.

SD: Standard deviation.

Statistical significance p ⩽ 0.05.
